daily semaglutide injection Day 2: Wegovy (Semaglutide 2.4 mg weekly injection) Class: GLP-1 receptor agonist Avg Weight Loss: ~15% of baseline weight Dosing: Weekly subcutaneous FDA Approved: June 2021 for chronic weight management Pros Weekly GLP-1 Injection vs Daily

Here's the honest picture: Strong: Consistent positive results in animal studies Multiple mechanisms that make biological sense Good safety profile in research settings Decades of study without major red flags Weak: Limited human clinical trials Not FDA approved for any indication Long-term effects unknown Quality control issues with commercial products The peptide is stuck in an odd place

Most patients naturally reduce their protein intake along with overall calories, but protein requirements actually increase during rapid weight loss

Most people have more fragile capillary walls that are easily broken under the slight pressure of a needle

Appl Biochem Biotechnol 168:198205